Treatment of resistance to opicapone

Opicapone (opicapone) is a drug used to treat Parkinson's disease. It belongs to the COMT inhibitor class of drugs. COMT inhibitors mainly increase the effective concentration of dopamine in the brain by inhibiting catechol-O-methyltransferase (COMT), thereby alleviating the symptoms of Parkinson's disease patients. In some patients, long-term use of opicapone may lead to the development of drug resistance. Drug resistance means that the drug gradually loses its efficacy during treatment, and corresponding treatment measures need to be taken.

Doctors will gradually increase the dose of Opicapone based on the patient's specific conditions to improve the efficacy of the drug. Dosage adjustments should be made under the guidance of a doctor, and drug dosages should not be changed at will to avoid unnecessary side effects. Another way to deal with resistance is to combine opicapone with other anti-Parkinsonian drugs, such as dopamine agonists or deep brain stimulation, to increase the effectiveness of the treatment. In some cases, it may be necessary to consider switching to another class of medication to treat Parkinson's disease. However, everyone’s physique is different and their resistance to drugs is also different. If you feel unwell, please inform your doctor in time.

Opicapone has not yet been launched in the country, so it is not covered by medical insurance. The European version of Opicapone’s original drug specifications listed overseasThe price per box of 50mg*90 capsules is around RMB 6,000 (the price may fluctuate due to the exchange rate). There is currently no generic version of Opicapone on the market. For more drug information and specific prices, please consult Yaode’s medical consultant.